James B Breitmeyer's Net Worth
$2.42 Million
Who is James B Breitmeyer?
James B Breitmeyer has an estimated net worth of $2.42 Million. This is based on reported shares across multiple companies, which include APPLIED MOLECULAR EVOLUTION INC, ZOGENIX, INC., Oncternal Therapeutics, Inc., OTONOMY, INC., and CADENCE PHARMACEUTICALS INC.
SEC CIK
James B Breitmeyer's CIK is 0001244823
Past Insider Trading and Trends
2019 was James B Breitmeyer's most active year for acquiring shares with 8 total transactions. James B Breitmeyer's most active month to acquire stocks was the month of May. 2023 was James B Breitmeyer's most active year for disposing of shares, totalling 8 transactions. James B Breitmeyer's most active month to dispose stocks was the month of February. 2019 saw James B Breitmeyer paying a total of $89,900.00 for 555,704 shares, this is the most they've acquired in one year. In 2019 James B Breitmeyer cashed out on 120,000 shares for a total of $500,000.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
APPLIED MOLECULAR EVOLUTION INC No price found
VP PHARMACEUTICAL OPERATIONSJames B Breitmeyer owns 33,172 units of Common Stock.acquired a total of 18,611 shares in APPLIED MOLECULAR EVOLUTION INC at a cost of $37,665.54.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +17.36% | 4.91K |
$1.74 | $8,538.18 | 33.17K |
Feb 9
| |||
Form 4
| +28.47% | 6.26K |
$1.74 | $10,899.36 | 28.27K |
Jan 2
| |||
Form 4
| +51.10% | 7.44K |
$2.45 | $18,228.00 | 22K |
Sep 19
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ZOGENIX, INC. No price found
InvestorJames B Breitmeyer used to own units in Common Stock but no longer holds any shares there.acquired a total of 10,000 shares in ZOGENIX, INC. at a cost of $89,900.00, James also disposed a total of 11,250 shares of ZOGENIX, INC. equalling to $500,000.00.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -1.25K |
—
|
—
|
0
|
Mar 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 27
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 29
| |||
Form 4
|
—
|
0
|
$29.50 | -$205,050.00 | 1.25K |
Scheduled
|
Dec 16
| ||
Form 4
|
—
|
0
|
$29.50 | -$205,050.00 | 1.25K |
Scheduled
|
Nov 25
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 25
| |||
| No matching records found | |||||||||
Oncternal Therapeutics, Inc. (ONCT) Snapshot price: $4.47
Chief Executive OfficerJames B Breitmeyer owns 443,034 units of Common Stock which is worth $1,980,361.98. From 2019 to 2024 James B Breitmeyer acquired a total of 569,773 shares in Oncternal Therapeutics, Inc., James also disposed a total of 126,740 shares of Oncternal Therapeutics, Inc. equalling to $70,904.76.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 14
| |||
Form 4
| -10.79% | -55.44K |
$0.50 | -$27,503.79 | 458.46K |
Jan 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 2
| |||
Form 4
| -9.19% | -52.00K |
$0.36 | -$18,719.64 | 513.9K |
Jul 3
| |||
Form 4
| +322.28% | 150K |
$0.29 | $43,929.75 | 196.54K |
Apr 13 - Apr 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 21
| |||
Form 4
| -4.89% | -29.12K |
$1.02 | -$29,700.36 | 565.9K |
Jan 3
| |||
Form 4
| +52.32% | 204.38K |
—
|
—
| 595.02K |
Jul 28
| |||
Form 4
| +116.04% | 25K |
$1.68 | $42,080.00 | 46.54K |
Jan 27
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 20
| |||
Form 4
| +52.96% | 135.35K |
—
|
—
| 390.94K |
Jan 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 27 - Feb 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 11
| |||
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Sep 12
| |||
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Mar 17
| |||
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Jan 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 18
| |||
Form 4
|
∞
| 277.87K |
—
|
—
| 277.87K |
Jun 7
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
OTONOMY, INC. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 19
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
CADENCE PHARMACEUTICALS INC No price found
EVP, CMO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||